Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura

Clinical and Experimental Immunology

Volumn 179, Issue 3, 2015, Pages 414-425

  Becerra, E ^a   Scully, M A ^b   Leandro, M J ^a   Heelas, E O ^b   Westwood, J P ^b   De La Torre, I ^c   Cambridge, G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

B cells; BAFF; BAFF R; Rituximab; TTP

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; CD19 ANTIGEN; CD23 ANTIGEN; CD27 ANTIGEN; CORTICOSTEROID; IMMUNOGLOBULIN D; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; B CELL ACTIVATING FACTOR RECEPTOR; BIOLOGICAL MARKER; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TNFSF13B PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BLOOD SAMPLING; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOPHENOTYPING; MALE; MEMORY CELL; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; ADOLESCENT; BLOOD; CELL CULTURE; CELL DIFFERENTIATION; DISEASE COURSE; DRUG EFFECTS; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADAM PROTEINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; BIOMARKERS; CELL DIFFERENTIATION; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RITUXIMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922780777     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12472     Document Type: Article

References (53)

1. Scully M, Hunt BJ, Benjamin S etal. for the British Committee for Standards in H. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158:323-335.
2. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89:3097-3103.
3. Furlan M, Robles R, Galbusera M etal. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-1584.
4. Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7:1703-1710.
5. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8:1201-1208.
6. Maloney DG, Liles TM, Czerwinski DK etal. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84:2457-2466.
7. Edwards JC, Szczepanski L, Szechinski J etal. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-2581.
8. Jones RB, Tervaert JW, Hauser T etal. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-220.
9. Heidel F, Lipka DB, von Auer C, Huber C, Scharrer I, Hess G. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007; 97:228-233.
10. Scully M, Cohen H, Cavenagh J etal. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136:451-461.
11. Scully M, McDonald V, Cavenagh J etal. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118:1746-1753.
12. Froissart A, Buffet M, Veyradier A etal. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40:104-111.
13. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 2013; 11:481-490.
14. Hie M, Gay J, Galicier L etal. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 2014; 124:204-210.
15. Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006; 65 (Suppl. 3):iii34-36.
16. + memory B cells. Immunity 2007; 26:205-213.
17. Warnatz K, Salzer U, Rizzi M etal. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci USA 2009; 106:13945-13950.
18. Thomas MR, Machin SJ, Mackie I, Scully MA. B cell activating factor is elevated in acute idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2011; 155:620-622.
19. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54:723-732.
20. Seror R, Sordet C, Guillevin L etal. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007; 66:351-357.
21. Cambridge G, Isenberg DA, Edwards JC etal. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008; 67:1011-1016.
22. + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998; 188:1679-1689.
23. Wu YC, Kipling D, Dunn-Walters DK. The relationship between CD27 negative and positive B cell populations in human peripheral blood. Front Immunol 2011; 2:81.
24. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001; 167:3610-3618.
25. Weller S, Braun MC, Tan BK etal. Human blood IgM 'memory' B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 2004; 104:3647-3654.
26. Scully M. Rituximab in the treatment of TTP. Hematology 2012; 17 (Suppl. 1):S22-24.
27. Bansal AS, Haeney MR, Cochrane S etal. Serum soluble CD23 in patients with hypogammaglobulinaemia. Clin Exp Immunol 1994; 97:239-241.
28. Cambridge G, Perry HC, Nogueira L etal. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun 2013; 50:67-76.
29. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129:93-100.
30. Kreuzaler M, Rauch M, Salzer U etal. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol 2012; 188:497-503.
31. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54:2377-2386.
32. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JCW. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:613-620.
33. Popa C, Leandro MJ, Cambridge G, Edwards JCW. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology 2007; 46:626-630.
34. Vital EM, Dass S, Buch MH etal. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011; 63:3038-3047.
35. Bhat NM, Kantor AB, Bieber MM, Stall AM, Herzenberg LA, Teng NN. The ontogeny and functional characteristics of human B-1 (CD5+ B) cells. Int Immunol 1992; 4:243-252.
36. Berkowska MA, Driessen GJ, Bikos V etal. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 2011; 118:2150-2158.
37. Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annu Rev Immunol 2009; 27:267-285.
38. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58:1566-1575.
39. + B cells. Exp Hematol 2005; 33:480-486.
40. Anolik JH, Barnard J, Owen T etal. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56:3044-3056.
41. Anolik JH, Friedberg JW, Zheng B etal. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122:139-145.
42. Iwata S, Saito K, Tokunaga M, Tanaka Y. Persistent memory B cell down-regulation after 6-year remission induced by rituximab therapy in patients with systemic lupus erythematosus. Lupus 2013; 22:538-540.
43. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 1991; 173:487-489.
44. Ireland JM, Unanue ER. Processing of proteins in autophagy vesicles of antigen-presenting cells generates citrullinated peptides recognized by the immune system. Autophagy 2012; 8:429-430.
45. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM. BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol 2005; 36:1113-1119.
46. de la Torre I, Moura RA, Leandro MJ, Edwards J, Cambridge G. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. Ann Rheum Dis 2010; 69:2181-2188.
47. Kaur K, Chowdhury S, Greenspan NS, Schreiber JR. Decreased expression of tumor necrosis factor family receptors involved in humoral immune responses in preterm neonates. Blood 2007; 110:2948-2954.
48. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009; 9:491-502.
49. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007; 179:7276-7286.
50. Sorvillo N, Pos W, van den Berg LM etal. The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood 2012; 119:3828-3835.
51. Scully M, Brown J, Patel R, McDonald V, Brown CJ, Machin S. Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link. J Thromb Haemost 2010; 8:257-262.
52. Coppo P, Busson M, Veyradier A etal. HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians. J Thromb Haemost 2010; 8:856-859.
53. Woo YJ, Yoon BY, Jhun JY etal. Regulation of B cell activating factor (BAFF) receptor expression by NF-KappaB signaling in rheumatoid arthritis B cells. Exp Mol Med 2011; 43:350-357.